Skip to content
Screener

Replimune Group REPL Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.57M+235%
Regenxbio logo
RegenxbioRGNX
$43.87M-13.1%
Immunome logo
ImmunomeIMNM
$3.94M+20.6%
CG Oncology logo
CG OncologyCGON
$5.73M+494%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$288K-57.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.15B+195%
Enterprise value$1.1B+199%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemNine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Operating cash flows from operating leases$900$876
Operating cash flows from finance leases$1,553$1,594
Financing cash flows from finance leases$538$436
Right-of-use asset obtained in exchange for new operating lease liabilities
Weighted-average remaining lease term - operating leases4.04.9
Weighted-average remaining lease term - financing leases13.614.6
Weighted-average discount rate - operating leases10.4%10.3%
Weighted-average discount rate - financing leases8.3%8.3%

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's operating lease ROU assets?
Replimune Group (REPL) reported operating lease ROU assets of 10.4% in Q4 2025.
How has Replimune Group's operating lease ROU assets changed year-over-year?
Replimune Group's operating lease ROU assets increased by 1.0% year-over-year, from 10.3% to 10.4%.
What is the long-term trend for Replimune Group's operating lease ROU assets?
Over 4 years (2021 to 2025), Replimune Group's operating lease ROU assets has grown at a -8.7% compound annual growth rate (CAGR), from 575,100,000% to 399,800,000%.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Replimune Group's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude